Doctor profile · Federal record

Dr. Inderjit Mehmi, M.D.

Hematology & Oncology Physician (CMS: Medical Oncology) · Internal Medicine Physician · Los Angeles, CA

  • NPI 1801092705
  • Accepts Medicare
  • MIPS 84.1 / 100 · 2023
  • 19 yrs in practice
  • Licensed in 2 states
  • Male
  • Group practice
  • No sanctions

Practice & contact

Operates at 2 locations .

NPPES Updated May 11, 2026
Primary practice
11800 Wilshire Blvd Fl 3
Los Angeles, CA 900256602
(310) 231-2121
fax (310) 582-7996
Additional location
1 Medical Center Drive
Morgantown, WV 26506
(304) 293-4229
fax (304) 285-7126
Mailing address
Medical Center Dr
Morgantown, WV 26506

Credentials & registration

NPPES · NUCC
NPI registered
June 2007 — 19 yrs on file
Profile last updated
February 5, 2020
Year of graduation
2007 — 19 yrs since
Specialty taxonomy
207RH0003X — NUCC code
State licenses (2)
West Virginia #24937 · Indiana #01070849A
Medicaid
WV #3810024009

Federal sanctions & exclusions

OIG LEIE Updated May 11, 2026

No sanctions, exclusions or revocations on file

Checked against OIG LEIE on NPI 1801092705. Last verified May 11, 2026.

Medicare procedures · 2023

Top services delivered

CMS Provider Utilization
Total services
55,492
Distinct HCPCS
10
Medicare allowed
$2,852,515
HCPCS Description Services Patients Avg allowed
J9271 Injection, pembrolizumab, 1 mg 30,408 25 $54
J9299 Injection, nivolumab, 1 mg 9,500 12 $30
J9228 Injection, ipilimumab, 1 mg 3,903 11 $164
J0897 Injection, denosumab, 1 mg 1,920 11 $23
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count 1,313 536 $8
80053 Blood test, comprehensive group of blood chemicals 1,207 509 $10
36415 Insertion of needle into vein for collection of blood sample 874 560 $8
99214 Established patient office or other outpatient visit, 30-39 minutes 717 236 $141
84100 Phosphate level 551 227 $5
84550 Uric acid level, blood 525 200 $4

In context: peer comparison

Among 50 peers in Los Angeles Hematology & Oncology Physician, average services per provider: 1,244. This provider delivers 45× the peer median.

Open Payments

Industry payments received

CMS Open Payments
All-time total
$23,158
Transactions
36
Manufacturers
6
Payer (manufacturer) Industry Txns Amount
E.R. Squibb & Sons, L.L.C. 12 $14,169.43
Immunocore Limited 15 $6,515.68
Merck Sharp & Dohme LLC 2 $2,230.00
TriSalus Life Sciences, INC. 1 $130.07
Emd Serono, INC. 4 $78.57
Array Biopharma INC 2 $33.77

By nature of payment

Compensation for Services Other Than Consulting, Including Serving As Faculty or As A Speaker at A Venue Other Than A Continuing Education Program
$12,558
Honoraria
$5,900
Consulting Fee
$2,335
Travel and Lodging
$1,563
Food and Beverage
$802

Medicare Part D · 2023

Top prescriptions

CMS Part D Prescriber
Total claims
278
Patients
14
Total drug cost
$1,397,063
Drug Type Claims Patients Total cost
Letrozole Generic 59 14 $3,747
Prednisone Generic 25 0 $282
Anastrozole Generic 21 0 $797
Mektovi (Binimetinib) Brand 21 0 $272,565
Braftovi (Encorafenib) Brand 19 0 $309,767
Tafinlar (Dabrafenib Mesylate) Brand 19 0 $255,882
Mekinist (Trametinib Dimethyl Sulfoxide) Brand 18 0 $281,492
Levothyroxine Sodium Generic 16 0 $323
Ondansetron Hcl Generic 16 0 $99
Ondansetron Odt (Ondansetron) Brand 15 0 $133

Hospital affiliations

CMS Hospital Compare

Frequently asked questions

Auto-generated from federal data
What is Dr. Inderjit Mehmi's medical specialty?
Dr. Inderjit Mehmi practices Hematology & Oncology Physician in Los Angeles, CA.
Where does Dr. Inderjit Mehmi practice?
Dr. Inderjit Mehmi practices at 11800 Wilshire Blvd Fl 3, Los Angeles, CA 900256602. Office phone: 3102312121.
What is Dr. Inderjit Mehmi's NPI?
Dr. Inderjit Mehmi's National Provider Identifier (NPI) is 1801092705, issued by NPPES.
Does Dr. Inderjit Mehmi accept Medicare assignment?
Yes. Dr. Inderjit Mehmi accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Inderjit Mehmi commonly perform?
Top Medicare-reported procedures in 2023: Injection, pembrolizumab, 1 mg (HCPCS J9271); Injection, nivolumab, 1 mg (HCPCS J9299); Injection, ipilimumab, 1 mg (HCPCS J9228). Source: CMS Medicare Physician & Other Practitioners file.